The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 20, 2021

Filed:

Jan. 02, 2018
Applicant:

The Council of the Queensland Institute of Medical Research, Herston, AU;

Inventors:

Rajiv Khanna, Herston, AU;

Dasari Vijayendra, The Gap, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/245 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/245 (2013.01); C07K 14/005 (2013.01); C12N 5/0638 (2013.01); C12N 7/00 (2013.01); A61K 2039/572 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/40 (2013.01); C12N 2501/998 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16222 (2013.01); C12N 2710/16234 (2013.01);
Abstract

An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.


Find Patent Forward Citations

Loading…